[1] L. Brewster, E. M. Brey, and H. P. Greisler, “Blood Vessels,” Princ. Tissue Eng. Fourth Ed., pp. 793–812, 2013.
[2] S. Li, D. Sengupta, and S. Chien, “Vascular tissue engineering: from in vitro to in situ,” Wiley Interdiscip. Rev. Syst. Biol. Med., vol. 6, no. 1, pp. 61–76, Jan. 2014.
[3] Z. Wang, S. M. Mithieux, and A. S. Weiss, “Fabrication Techniques for Vascular and Vascularized Tissue Engineering,” Adv. Healthc. Mater., vol. 8, no. 19, Oct. 2019.
[4] M. Potente and T. Mäkinen, “Vascular heterogeneity and specialization in development and disease,” Nat. Rev. Mol. Cell Biol., vol. 18, no. 8, pp. 477–494, 2017.
[5] J. Schöneberg et al., “Engineering biofunctional in vitro vessel models using a multilayer bioprinting technique,” Sci. Reports 2018 81, vol. 8, no. 1, pp. 1–13, Jul. 2018.
[6] J. E. Wagenseil and R. P. Mecham, “Vascular extracellular matrix and arterial mechanics,” Physiol. Rev., vol. 89, no. 3, pp. 957–989, Jul. 2009.
[7] H. Ardalani, A. H. Assadi, and W. L. Murphy, “Structure, function, and development of blood vessels: Lessons for tissue engineering,” Eng. Transl. Med., vol. 9781447143, pp. 155–182, May 2014.
[8] F. Wolf, F. Vogt, T. Schmitz-Rode, S. Jockenhoevel, and P. Mela, “Bioengineered vascular constructs as living models for in vitro cardiovascular research,” Drug Discov. Today, vol. 21, no. 9, pp. 1446–1455, Sep. 2016.
[9] W. J. Zhang, W. Liu, L. Cui, and Y. Cao, “Tissue engineering of blood vessel,” J. Cell. Mol. Med., vol. 11, no. 5, pp. 945–957, Sep. 2007.
[10] Y. Li et al., “Engineering cell alignment in vitro,” Biotechnol. Adv., vol. 32, no. 2, pp. 347–365, Mar. 2014.
[11] M. Tennant and J. K. McGeachie, “BLOOD VESSEL STRUCTURE AND FUNCTION: A BRIEF UPDATE ON RECENT ADVANCES,” Aust. N. Z. J. Surg., vol. 60, no. 10, pp. 747–753, 1990.
[12] J. Frösen and A. Joutel, “Smooth muscle cells of intracranial vessels: from development to disease,” Cardiovasc. Res., vol. 114, no. 4, pp. 501–512, Mar. 2018.
[13] S. Moosmang et al., “Dominant role of smooth muscle L-type calcium channel Cav1.2 for blood pressure regulation,” EMBO J., vol. 22, no. 22, pp. 6027–6034, Nov. 2003.
[14] D. G. Johns, R. C. Webb, and J. R. Charpie, “Impaired ceramide signalling in spontaneously hypertensive rat vascular smooth muscle: A possible mechanism for augmented cell proliferation,” J. Hypertens., vol. 19, no. 1, pp. 63–70, 2001.
[15] F. V. Brozovich, C. J. Nicholson, C. V. Degen, Y. Z. Gao, M. Aggarwal, and K. G. Morgan, “Mechanisms of Vascular Smooth Muscle Contraction and the Basis for Pharmacologic Treatment of Smooth Muscle Disorders,” Pharmacol. Rev., vol. 68, no. 2, p. 476, Apr. 2016.
[16] J. Eble and S. Niland, “The Extracellular Matrix of Blood Vessels,” Curr. Pharm. Des., vol. 15, no. 12, pp. 1385–1400, Mar. 2009.
[17] G. Bergers and S. Song, “The role of pericytes in blood-vessel formation and maintenance,” Neuro. Oncol., vol. 7, no. 4, pp. 452–464, Oct. 2005.
[18] L. Claesson-Welsh, “Vascular permeability - The essentials,” Ups. J. Med. Sci., vol. 120, no. 3, pp. 135–143, 2015.
[19] S. Azzi, J. K. Hebda, and J. Gavard, “Vascular Permeability and Drug Delivery in Cancers,” Front. Oncol., vol. 3, 2013.
[20] A. M. Dvorak, S. Kohn, E. S. Morgan, P. Fox, J. A. Nagy, and H. F. Dvorak, “The vesiculo-vacuolar organelle (VVO): a distinct endothelial cell structure that provides a transcellular pathway for macromolecular extravasation,” J. Leukoc. Biol., vol. 59, no. 1, pp. 100–115, Jan. 1996.
[21] V. Pade and S. Stavchansky, “Estimation of the relative contribution of the transcellular and paracellular pathway to the transport of passively absorbed drugs in the Caco-2 cell culture model,” Pharmaceutical Research, vol. 14, no. 9. pp. 1210–1215, 1997.
[22] Y. Komarova and A. B. Malik, “Regulation of Endothelial Permeability via Paracellular and Transcellular Transport Pathways,” Annu. Rev. Physiol., vol. 72, no. 1, pp. 463–493, Mar. 2010.
[23] E. Vandenbroucke, D. Mehta, R. Minshall, and A. B. Malik, “Regulation of endothelial junctional permeability,” Ann. N. Y. Acad. Sci., vol. 1123, pp. 134–145, 2008.
[24] D. Radke et al., “Tissue Engineering at the Blood-Contacting Surface: A Review of Challenges and Strategies in Vascular Graft Development,” Adv. Healthc. Mater., vol. 7, no. 15, p. 1701461, Aug. 2018.
[25] D. Kugelmann, L. T. Rotkopf, M. Y. Radeva, A. Garcia-Ponce, E. Walter, and J. Waschke, “Histamine causes endothelial barrier disruption via Ca2+-mediated RhoA activation and tension at adherens junctions,” Sci. Reports 2018 81, vol. 8, no. 1, pp. 1–14, Sep. 2018.
[26] L. Duluc and B. Wojciak-Stothard, “Rho GTPases in the regulation of pulmonary vascular barrier function,” Cell Tissue Res., vol. 355, no. 3, pp. 675–685, 2014.
[27] A. Nusrat, J. R. Turner, and J. L. Madara, “IV. Regulation of tight junctions by extracellular stimuli: nutrients, cytokines, and immune cells,” Am. J. Physiol. Liver Physiol., vol. 279, no. 5, pp. G851–G857, Nov. 2000.
[28] A. B. Moy et al., “Histamine and thrombin modulate endothelial focal adhesion through centripetal and centrifugal forces.,” J. Clin. Invest., vol. 97, no. 4, pp. 1020– 1027, Feb. 1996.
[29] G. Majno, S. M. Shea, and M. Leventhal, “Endothelial contraction induced by histamine-type mediators: an electron microscopic study.,” J. Cell Biol., vol. 42, no. 3, pp. 647–672, 1969.
[30] J. Silberman, A. Jha, H. Ryan, T. Abbate, and E. Moore, “Modeled vascular microenvironments: immune-endothelial cell interactions in vitro,” Drug Deliv. Transl. Res., vol. 11, no. 6, pp. 2482–2495, Apr. 2021.
[31] S. Huveneers et al., “Vinculin associates with endothelial VE-cadherin junctions to control force-dependent remodeling,” J. Cell Biol., vol. 196, no. 5, pp. 641–652, 2012.
[32] K. Ashina et al., “Histamine induces vascular hyperpermeability by increasing blood flow and endothelial barrier disruption in vivo,” PLoS One, vol. 10, no. 7, pp. 1–16, 2015.
[33] D. Mehta and A. B. Malik, “Signaling mechanisms regulating endothelial permeability,” Physiol Rev, vol. 86, no. 1, pp. 279–367, 2006.
[34] H. Suzuki and K. Kou, “Direct and indirect effects of histamine on the smooth muscle cells of the guinea-pig main pulmonary artery,” Pflügers Arch. 1983 3991, vol. 399, no. 1, pp. 46–53, Sep. 1983.
[35] J. R. Burgoyne and P. Eaton, “Oxidant Sensing by Protein Kinases A and G Enables Integration of Cell Redox State with Phosphoregulation,” Sensors 2010, Vol. 10, Pages 2731-2751, vol. 10, no. 4, pp. 2731–2751, Mar. 2010.
[36] L. J. Ignarro, “Endothelium-Derived Nitric Oxide: Pharmacology and Relationship to the Actions of Organic Nitrate Esters,” Pharm. Res. 1989 68, vol. 6, no. 8, pp. 651–659, 1989.
[37] C. R. Triggle, S. M. Samuel, S. Ravishankar, I. Marei, G. Arunachalam, and H. Ding, “The endothelium: Influencing vascular smooth muscle in many ways,” Can. J. Physiol. Pharmacol., vol. 90, no. 6, pp. 713–718, 2012.
[38] D. M. Dudzinski, J. Igarashi, D. Greif, and T. Michel, “The regulation and pharmacology of endothelial nitric oxide synthase,” Annu. Rev. Pharmacol. Toxicol., vol. 46, pp. 235–276, 2006.
[39] H. J. Knot and M. T. Nelson, “Regulation of arterial diameter and wall [Ca2+] in cerebral arteries of rat by membrane potential and intravascular pressure,” J. Physiol., vol. 508, no. 1, pp. 199–209, Apr. 1998.
[40] L. Bacakova et al., “The Role of Vascular Smooth Muscle Cells in the Physiology and Pathophysiology of Blood Vessels,” Muscle Cell Tissue - Curr. Status Res. F., Oct. 2018.
[41] B. J. Van Varik, R. J. M. W. Rennenberg, C. P. Reutelingsperger, A. A. Kroon, P. W. De Leeuw, and L. J. Schurgers, “Mechanisms of arterial remodeling: Lessons from genetic diseases,” Front. Genet., vol. 3, no. DEC, 2012.
[42] S. T. Lust, C. M. Shanahan, R. J. Shipley, P. Lamata, and E. Gentleman, “Design considerations for engineering 3D models to study vascular pathologies in vitro,” Acta Biomater., vol. 132, pp. 114–128, Sep. 2021.
[43] R. M. Nerem and D. Seliktar, “Vascular Tissue Engineering,” http://dx.doi.org/10.1146/annurev.bioeng.3.1.225, vol. 3, pp. 225–243, Nov. 2003.
[44] T. Hartung, “Food for Thought Look Back in Anger – What Clinical Studies Tell Us About Preclinical Work,” ALTEX, vol. 30, pp. 275–291, 2013.
[45] R. Mangipudy, J. Burkhardt, and V. J. Kadambi, “Use of animals for toxicology testing is necessary to ensure patient safety in pharmaceutical development,” Regul. Toxicol. Pharmacol., vol. 70, no. 2, pp. 439–441, 2014.
[46] L. J. Marshall and A. N. Rowan, “Advances in alternative non-animal testingmethods represent a way to find newtreatments for patients,” Eur. J. Intern. Med., vol. letter, pp. 1–2, 2017.
[47] S. S. Sparrow et al., “Opportunities to minimise animal use in pharmaceutical regulatory general toxicology : A cross-company review,” Regul. Toxicol. Pharmacol., vol. 61, no. 2, pp. 222–229, 2011.
[48] S. K. Doke and S. C. Dhawale, “Alternatives to animal testing : A review,” Saudi Pharm. J., vol. 23, no. 3, pp. 223–229, 2015.
[49] S. Garattini and G. Grignaschi, “Animal testing is still the best way to fi nd new treatments for patients,” Eur. J. Intern. Med., vol. 39, pp. 32–35, 2017.
[50] S. Scholz et al., “A European perspective on alternatives to animal testing for environmental hazard identification and risk assessment,” Regul. Toxicol. Pharmacol., vol. 67, no. 3, pp. 506–530, 2013.
[51] M. Balls, “Future Improvements : Replacement In Vitro Methods,” ILAR J., vol. 43, pp. 69–73, 2002.
[52] K. Ziółkowska, R. Kwapiszewski, and Z. Brzózka, “Microfluidic devices as tools for mimicking the in vivo environment,” New J. Chem., vol. 35, no. 5, pp. 979–990, 2011.
[53] K. Gold, A. K. Gaharwar, and A. Jain, “Emerging trends in multiscale modeling of vascular pathophysiology: Organ-on-a-chip and 3D printing,” Biomaterials, vol. 196, pp. 2–17, Mar. 2019.
[54] D. G. Seifu, A. Purnama, K. Mequanint, and D. Mantovani, “Small-diameter vascular tissue engineering,” Nat. Rev. Cardiol., vol. 10, no. 7, pp. 410–421, Jul. 2013.
[55] S. Kim, W. Kim, S. Lim, and J. S. Jeon, “Vasculature-on-a-chip for in vitro disease models,” Bioengineering, vol. 4, no. 1, Mar. 2017.
[56] S. Ahadian et al., “Organ-On-A-Chip Platforms: A Convergence of Advanced Materials, Cells, and Microscale Technologies,” Adv. Healthc. Mater., vol. 7, no. 2, Jan. 2018.
[57] J. M. Rhodes and M. Simons, “The extracellular matrix and blood vessel formation: not just a scaffold,” J. Cell. Mol. Med., vol. 11, no. 2, pp. 176–205, Mar. 2007.
[58] V. Hosseini et al., “Healthy and diseased in vitro models of vascular systems,” Lab Chip, vol. 21, no. 4, pp. 641–659, Feb. 2021.
[59] K. H. Nam, A. S. T. Smith, S. Lone, S. Kwon, and D. H. Kim, “Biomimetic 3D Tissue Models for Advanced High-Throughput Drug Screening,” J. Lab. Autom., vol. 20, no. 3, pp. 201–215, Jun. 2015.
[60] J. S. Choi, Y. Piao, and T. S. Seo, “Fabrication of a circular PDMS microchannel for constructing a three-dimensional endothelial cell layer,” Bioprocess Biosyst. Eng., vol. 36, no. 12, pp. 1871–1878, Nov. 2013.
[61] J. W. Song et al., “Microfluidic Endothelium for Studying the Intravascular Adhesion of Metastatic Breast Cancer Cells,” PLoS One, vol. 4, no. 6, p. e5756, Jun. 2009.
[62] H. Kaji, T. Yokoi, T. Kawashima, and M. Nishizawa, “Directing the flow of medium in controlled cocultures of HeLa cells and human umbilical vein endothelial cells with a microfluidic device,” Lab Chip, vol. 10, no. 18, pp. 2374–2379, Aug. 2010.
[63] K. Sakaguchi et al., “In vitro engineering of vascularized tissue surrogates.,” Sci. Rep., vol. 3, p. 1316, 2013.
[64] M. A. Redd et al., “Patterned human microvascular grafts enable rapid vascularization and increase perfusion in infarcted rat hearts,” Nat. Commun. 2019 101, vol. 10, no. 1, pp. 1–14, Feb. 2019.
[65] J. Pauty et al., “A Vascular Endothelial Growth Factor-Dependent Sprouting Angiogenesis Assay Based on an In Vitro Human Blood Vessel Model for the Study of Anti-Angiogenic Drugs,” EBioMedicine, vol. 27, pp. 225–236, Jan. 2018.
[66] A. Tan, K. Fujisawa, Y. Yukawa, and Y. T. Matsunaga, “Bottom-up fabrication of artery-mimicking tubular co-cultures in collagen-based microchannel scaffolds,” Biomater. Sci., vol. 4, no. 10, pp. 1503–1514, 2016.
[67] F. Kabirian, B. Ditkowski, A. Zamanian, M. F. Hoylaerts, M. Mozafari, and R. Heying, “Controlled NO-Release from 3D-Printed Small-Diameter Vascular Grafts Prevents Platelet Activation and Bacterial Infectivity,” ACS Biomater. Sci. Eng., vol. 5, no. 5, pp. 2284–2296, May 2019.
[68] B. Cheng, Y. M. Xing, N. C. Shih, J. P. Weng, and H. C. Lin, “The formulation and characterization of 3D printed grafts as vascular access for potential use in hemodialysis,” RSC Adv., vol. 8, no. 28, pp. 15471–15479, Apr. 2018.
[69] K. Hoon Song et al., “Complex 3D-Printed Microchannels within Cell-Degradable Hydrogels,” Adv. Funct. Mater., vol. 28, no. 31, p. 1801331, Aug. 2018.
[70] J. S. Miller et al., “Rapid casting of patterned vascular networks for perfusable engineered three-dimensional tissues,” Nat. Mater., vol. 11, no. 7, pp. 768–774, 2012.
[71] X. Cao, S. Maharjan, R. Ashfaq, J. Shin, and Y. S. Zhang, “Bioprinting of Small- Diameter Blood Vessels,” Engineering, vol. 7, no. 6, pp. 832–844, Jun. 2021.
[72] M. Abudupataer et al., “Bioprinting a 3D vascular construct for engineering a vessel-on-a-chip,” Biomed. Microdevices, vol. 22, no. 1, p. 10, Mar. 2020.
[73] Q. Pi et al., “Digitally Tunable Microfluidic Bioprinting of Multilayered Cannular Tissues,” Adv. Mater., vol. 30, no. 43, p. 1706913, Oct. 2018.
[74] N. Brandenberg, M. P. Lutolf, N. Brandenberg, and M. P. Lutolf, “In Situ Patterning of Microfluidic Networks in 3D Cell-Laden Hydrogels,” Adv. Mater., vol. 28, no. 34, pp. 7450–7456, Sep. 2016.
[75] C. K. Arakawa et al., “Multicellular Vascularized Engineered Tissues through User- Programmable Biomaterial Photodegradation,” Adv. Mater., vol. 29, no. 37, p. 1703156, Oct. 2017.
[76] K. A. Heintz et al., “Fabrication of 3D Biomimetic Microfluidic Networks in Hydrogels,” Adv. Healthc. Mater., vol. 5, no. 17, pp. 2153–2160, Sep. 2016.
[77] C. D. Devillard and C. A. Marquette, “Vascular Tissue Engineering: Challenges and Requirements for an Ideal Large Scale Blood Vessel,” Front. Bioeng. Biotechnol., vol. 9, p. 913, Oct. 2021.
[78] E. Ercolani, C. Del Gaudio, and A. Bianco, “Vascular tissue engineering of small- diameter blood vessels: reviewing the electrospinning approach,” J. Tissue Eng. Regen. Med., vol. 9, no. 8, pp. 861–888, Aug. 2015.
[79] C. K. Hashi et al., “Antithrombogenic modification of small-diameter microfibrous vascular grafts,” Arterioscler. Thromb. Vasc. Biol., vol. 30, no. 8, pp. 1621–1627, Aug. 2010.
[80] S. A. Sell, M. J. McClure, K. Garg, P. S. Wolfe, and G. L. Bowlin, “Electrospinning of collagen/biopolymers for regenerative medicine and cardiovascular tissue engineering,” Adv. Drug Deliv. Rev., vol. 61, no. 12, pp. 1007–1019, Oct. 2009.
[81] L. Buttafoco et al., “Electrospinning of collagen and elastin for tissue engineering applications,” Biomaterials, vol. 27, no. 5, pp. 724–734, Feb. 2006.
[82] S. Kim, H. Lee, M. Chung, and N. L. Jeon, “Engineering of functional, perfusable 3D microvascular networks on a chip,” Lab Chip, vol. 13, no. 8, pp. 1489–1500, Mar. 2013.
[83] C. Kim, J. Kasuya, J. Jeon, S. Chung, and R. D. Kamm, “A quantitative microfluidic angiogenesis screen for studying anti-angiogenic therapeutic drugs,” Lab Chip, vol. 15, no. 1, pp. 301–310, Dec. 2014.
[84] P. J. Schaner et al., “Decellularized vein as a potential scaffold for vascular tissue engineering,” J. Vasc. Surg., vol. 40, no. 1, pp. 146–153, Jul. 2004.
[85] M. Watanabe et al., “Construction of sinusoid-scale microvessels in perfusion culture of a decellularized liver,” Acta Biomater., vol. 95, pp. 307–318, Sep. 2019.
[86] Y. Gao et al., “Decellularized liver as a translucent ex vivo model for vascular embolization evaluation,” Biomaterials, vol. 240, p. 119855, May 2020.
[87] S. S. Rho, K. Ando, and S. Fukuhara, “Dynamic regulation of vascular permeability by vascular endothelial cadherin-mediated endothelial cell-cell junctions,” J. Nippon Med. Sch., vol. 84, no. 4, pp. 148–159, 2017.
[88] M. Trani and E. Dejana, “New insights in the control of vascular permeability: vascular endothelial-cadherin and other players,” Curr Opin Hematol, vol. 22, no. 3, pp. 267–272, May 2015.
[89] H. Schnittler, M. Taha, M. O. Schnittler, A. A. Taha, N. Lindemann, and J. Seebach, “Actin filament dynamics and endothelial cell junctions: the Ying and Yang between stabilization and motion,” Cell Tissue Res, vol. 355, no. 3, pp. 529–543, 2014.
[90] V. Hosseini et al., “Healthy and diseased in vitro models of vascular systems,” Lab Chip, vol. 21, no. 4, pp. 641–659, 2021.
[91] P. W. Alford, A. P. Nesmith, J. N. Seywerd, A. Grosberg, and K. K. Parker, “Vascular smooth muscle contractility depends on cell shape,” Integr. Biol., vol. 3, no. 11, pp. 1063–1070, Nov. 2011.
[92] K. E. Steucke, P. V. Tracy, E. S. Hald, J. L. Hall, and P. W. Alford, “Vascular smooth muscle cell functional contractility depends on extracellular mechanical properties,” J. Biomech., vol. 48, no. 12, pp. 3044–3051, Sep. 2015.
[93] J. S. Choi, Y. Piao, and T. S. Seo, “Circumferential alignment of vascular smooth muscle cells in a circular microfluidic channel,” Biomaterials, vol. 35, no. 1, pp. 63– 70, Jan. 2014.
[94] A. Tijore, J. M. Behr, S. A. Irvine, V. Baisane, and S. Venkatraman, “Bioprinted gelatin hydrogel platform promotes smooth muscle cell contractile phenotype maintenance,” Biomed. Microdevices, vol. 20, no. 2, pp. 1–10, Jun. 2018.
[95] P. Lacolley, V. Regnault, P. Segers, and S. Laurent, “Vascular smooth muscle cells and arterial stiffening: Relevance in development, aging, and disease,” Physiol. Rev., vol. 97, no. 4, pp. 1555–1617, Oct. 2017.
[96] S. Itai, H. Tajima, and H. Onoe, “Double-layer perfusable collagen microtube device for heterogeneous cell culture,” Biofabrication, vol. 11, no. 1, 2019.
[97] S. Itai and H. Onoe, “Flexibly Deformable Collagen Hydrogel Tube Reproducing Immunological Tissue Deformation of Blood Vessels as a Pharmacokinetic Testing Model,” Adv. Healthc. Mater., p. 2101509, Nov. 2021.
[98] K. Adamiak and A. Sionkowska, “Current methods of collagen cross-linking: Review,” Int. J. Biol. Macromol., vol. 161, pp. 550–560, Oct. 2020.
[99] D. J. S. Hulmes, “Collagen diversity, synthesis and assembly,” Collagen Struct. Mech., pp. 15–47, 2008.
[100] A. Sionkowska, S. Skrzyński, K. Śmiechowski, and A. Kołodziejczak, “Thereview of versatile application of collagen,” Polym. Adv. Technol., vol. 28, no. 1, pp. 4–9, Jan. 2017.
[101] B. Jiang, Y. Liu, B. Bhandari, and W. Zhou, “Impact of Caramelization on the Glass Transition Temperature of Several Caramelized Sugars. Part I: Chemical Analyses,” J. Agric. Food Chem., vol. 56, no. 13, pp. 5137–5147, Jul. 2008.
[102] D. Bouïs, G. A. P. Hospers, C. Meijer, G. Molema, and N. H. Mulder, “Endothelium in vitro: A review of human vascular endothelial cell lines for blood vessel-related research,” Angiogenesis, vol. 4, no. 2, pp. 91–102, 2001.
[103] N. A. Rahman et al., “Immortalized endothelial cell lines for in vitro blood–brain barrier models: A systematic review,” Brain Res., vol. 1642, pp. 532–545, Jul. 2016.
[104] Y. Cao et al., “The use of human umbilical vein endothelial cells (HUVECs) as an in vitro model to assess the toxicity of nanoparticles to endothelium: a review,” J. Appl. Toxicol., vol. 37, no. 12, pp. 1359–1369, Dec. 2017.
[105] D. Ribatti, B. Nico, and E. Crivellato, “The role of pericytes in angiogenesis,” Int. J. Dev. Biol., vol. 55, no. 3, pp. 261–268, Jun. 2011.
[106] D. Virgintino et al., “An intimate interplay between precocious, migrating pericytes and endothelial cells governs human fetal brain angiogenesis,” Angiogenesis, vol. 10, pp. 35–45, 2007.
[107] L. C. D. Smyth et al., “Unique and shared inflammatory profiles of human brain endothelia and pericytes,” J. Neuroinflammation, vol. 15, no. 1, pp. 1–18, May 2018.
[108] S. E. Sanders, J. L. Madara, D. K. McGuirk, D. S. Gelman, and S. P. Colgan, “(PDF) Assessment of inflammatory events in epithelial permeability: A rapid screening method using fluorescein dextrans.” [Online]. Available: https://www.researchgate.net/publication/14636320_Assessment_of_inflammatory_ events_in_epithelial_permeability_A_rapid_screening_method_using_fluorescein_d extrans. [Accessed: 26-Dec-2021].
[109] D. Günzel and A. S. L. Yu, “Claudins and the modulation of tight junction permeability,” Physiol. Rev., vol. 93, no. 2, pp. 525–569, 2013.
[110] V. H. Huxley, F. E. Curry, and R. H. Adamson, “Quantitative fluorescence microscopy on single capillaries: alpha-lactalbumin transport,” Am. J. Physiol. Circ. Physiol., vol. 252, no. 1, pp. H188–H197, 1987.
[111] A. C. Burton, “Relation of Structure to Function of the Tissues of the Wall of Blood Vessels,” Physiol. Rev., vol. 34, no. 4, pp. 619–642, Oct. 1954.
[112] T. Takeda, Y. Yamashita, S. Shimazaki, and Y. Mitsui, “Histamine decreases the permeability of an endothelial cell monolayer by stimulating cyclic AMP production through the H2-receptor,” J. Cell Sci., vol. 101, no. 4, pp. 745–750, 1992.
[113] E. B. Thangam et al., “The Role of Histamine and Histamine Receptors in Mast Cell-Mediated Allergy and Inflammation: The Hunt for New Therapeutic Targets,” Front. Immunol., vol. 9, Aug. 2018.
[114] M. Shahid, T. Tripathi, F. Sobia, S. Moin, M. Siddiqui, and R. A. Khan, “Histamine, histamine receptors, and their role in immunomodulation: An updated systematic review,” Open Immunol. J., vol. 2, no. 1, pp. 9–41, 2009.
[115] K. Ohmori et al., “Pharmacological, Pharmacokinetic and Clinical Properties of Olopatadine Hydrochloride, a New Antiallergic Drug,” Jpn. J. Pharmacol., vol. 88, no. 4, pp. 379–397, 2002.
[116] E. O. Meltzer et al., “Safety and efficacy of olopatadine hydrochloride nasal spray for the treatment of seasonal allergic rhinitis,” Ann. Allergy, Asthma Immunol., vol. 95, no. 6, pp. 600–606, Dec. 2005.
[117] F. M. White, FLUID MECHANICS. McGraw-Hill Higher Education, 2010.
[118] R. P. Franke, G. M, H. Schnittler, D. Seiffge, and C. Mittermayer, “Induction of human vascular endothelial stress fibres by fluid shear stress,” Nature, vol. 307, no. 16, pp. 648–649, 1984.
[119] H. Onoe, M. Kato-negishi, A. Itou, and S. Takeuchi, “Differentiation Induction of Mouse Neural Stem Cells in Hydrogel Tubular Microenvironments with Controlled Tube Dimensions,” Adv. Healthc. Mater., vol. 5, no. 9, pp. 1104–1111, 2016.
[120] T. Hayashi et al., “Endothelial cellular senescence is inhibited by nitric oxide: Implications in atherosclerosis associated with menopause and diabetes,” 2006.
[121] H. M. Finlay, J. G. Dixon, and P. B. Canham, “Fabric Organization of the Subendothelium of the Human Brain Artery by Polarized-Light Microscopy.”
[122] E. G. Nabel and E. Braunwald, “A Tale of Coronary Artery Disease and Myocardial Infarction,” N. Engl. J. Med., vol. 366, no. 1, pp. 54–63, Jan. 2012.
[123] L. Pantoni, “Cerebral small vessel disease: from pathogenesis and clinical characteristics to therapeutic challenges,” Lancet Neurol., vol. 9, no. 7, pp. 689–701, Jul. 2010.
[124] A. M. Handorf, Y. Zhou, M. A. Halanski, and W.-J. Li, “Tissue Stiffness Dictates Development, Homeostasis, and Disease Progression,” Organogenesis, vol. 11, no. 1, pp. 1–15, Jan. 2015.
[125] M. C. Murphy et al., “Decreased brain stiffness in Alzheimer’s disease determined by magnetic resonance elastography,” J. Magn. Reson. Imaging, vol. 34, no. 3, pp. 494–498, Sep. 2011.
[126] M. C. Lampi and C. A. Reinhart-King, “Targeting extracellular matrix stiffness to attenuate disease: From molecular mechanisms to clinical trials,” Sci. Transl. Med., vol. 10, no. 422, p. eaao0475, Jan. 2018.
[127] J. M. Spergel and A. S. Paller, “Atopic dermatitis and the atopic march,” J. Allergy Clin. Immunol., vol. 112, no. SUPPL. 6, pp. 118–127, 2003.
[128] D. Y. M. Leung et al., “New insights into atopic dermatitis Find the latest version : Science in medicine New insights into atopic dermatitis,” J Clin Invest., vol. 113, no. 7, pp. 651–657, 2004.
論文の公開元へ
